Turkish crisis may prove a boon for ASX borate junior


Published 16-AUG-2018 10:35 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Borates are naturally-occurring minerals containing boron and are integral in the natural world, being a micro nutrient required for all plant and animal life.

Yet they are increasingly important in the technological world as these materials form a strong industrial base, producing a broad range of goods and applications used in everyday life and modern technologies.

In fact, borates are non-substitutable in new world applications like electric vehicles, space shuttles, wind turbines, and smart phones.

Such is their importance that last year borates appeared in a European Commission report identifying a list of raw materials that are crucial to the European economy. Not only are they vital to Europe, these commodities are globally important.

However, borates are facing a supply crisis.

This is bad news for new technology manufacturers, but could be a win for borate producers...and their shareholders.

Borates production is tightly held, with just a few major players controlling the lion’s share of output.

Eti Maden, a Turkish state-owned mining and chemicals company is one major player. Back in 2016, the group claimed it had a market share of more than 50% of the world’s borate market, while controlling around 74% of the world’s borate reserves.

The second largest producer of borates globally is Rio Tinto (ASX:RIO). RIO claim to control 30% of global borate production, in a market that it estimates is growing at 6% per annum.

That said, RIO may be reaching peak production as its borate production only grew by 1% between 2016 and 2017, and production in 2017 was less than 2% higher than it was in 2014.

If this is correct and if there is little opportunity for additional capacity for the balance of the 20% of production, then by 2028, the Turkish Government could control a staggering 70% of the global market.

Turkey currency crisis

With the current Turkish currency and debt crisis, this could be a real problem for borates production and distribution.

The Turkish lira has lost more than 45% of its value this year, with calls from the Turkish president urging people to support the currency by ditching dollars and gold in exchange for lira.

However, the currency remains in freefall, hitting a fresh record low this week after US President Trump announced a doubling of steel and aluminium tariffs on Turkey in a retaliatory move... and there may be more tariffs to come.

This all means that producers outside of Turkey will become increasingly relevant.

Local borate investment opportunity

As for ASX investors, the opportunity to invest in borates specifically is slim. However, there is one largely undiscovered gem trading on the local bourse — American Pacific Borate and Lithium (ASX:ABR).

This is a junior, speculative stock so investors should seek professional financial advice if considering this stock for their portfolio.

ABR has the largest declared borate Mineral Resource Estimate — outside of Eti Maden and Rio Tinto — of 120.4m tonnes at 11.6% boric acid equivalent, for a total of 13.9m tonnes of contained boric acid.

In December 2017, ABR released a Scoping Study for a 25-year mine producing 246,000 tonnes of boric acid per annum to be built over two phases.

Capital expenditure for the first phase was US$98 million, inclusive of a 20% contingency. This delivered a post-tax, unlevered internal rate of return (IRR) of 41% and a net present value (NPV) of US$747 million (A$1.02 billion).

Since the release of the Scoping Study in December 2017, ABR now also expects to be able to monetise an additional by-product credit. It has also been working on ways to reduce operating expenses, while making its plant more flexible to reduce operational risk.

Considering that the Scoping Study delivered an EBITDA in the first year of full production of US$155 million, along with the fact that the Mineral Resource was increased by over 30% in February 2018, it could prove to be an even more substantial project.

Notably, RIO’s borate operations that delivered EBITDA margins of 38.7% and EBITDA of US$244m in 2017, is located within 100 kilometres of ABR’s Fort Cady project on the California-Nevada border.

In May 2018, ABR secured strategic cooperation agreements with two Chinese state-owned enterprises, Sinochem and Sinomach. Both companies rank higher than BHP and Rio Tinto on the list of Global Fortune 500 Companies.

As can be seen in the chart below, Turkey and ARB are forecast to raise their share of global supply through 2028.

In the past two weeks ABR has raised $4 million and is trading at around 20c a share. There are 190m ordinary shares on issue and around 22m options. At its current price of around 20c per share, ABR is trading at less than 5% of the NPV on its Scoping Study, suggesting there is plenty of upside for shareholders.

Next stop for ABR is a Definitive Feasibility Study (DFS) that it is seeking to complete in the current quarter. The completion of DFS will coincide with the lodgment of the water permit application, which is the final permit required for the company to construct and operate its initial phase of production of 82,000 tonnes of boric acid per annum.

Fort Cady site with drill rigs and pilot plant in October 2017

The company has signaled that this application may take up to 18 months but is planning on being construction ready by the middle of 2019, suggesting it is confident of a short permitting timetable.

It looks as though all is falling into place for ABR and current macro events could potentially be the icing on the cake for the company.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free